122 related articles for article (PubMed ID: 16454559)
1. BRCA1 and BRCA2 mutation screening using SmartCycler II high-resolution melt curve analysis.
Dufresne SD; Belloni DR; Wells WA; Tsongalis GJ
Arch Pathol Lab Med; 2006 Feb; 130(2):185-7. PubMed ID: 16454559
[TBL] [Abstract][Full Text] [Related]
2. A rapid and sensitive approach to mutation detection using real-time polymerase chain reaction and melting curve analyses, using BRCA1 as an example.
Pals G; Pindolia K; Worsham MJ
Mol Diagn; 1999 Sep; 4(3):241-6. PubMed ID: 10553024
[TBL] [Abstract][Full Text] [Related]
3. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
Roa BB; Boyd AA; Volcik K; Richards CS
Nat Genet; 1996 Oct; 14(2):185-7. PubMed ID: 8841191
[TBL] [Abstract][Full Text] [Related]
4. Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis.
Takano EA; Mitchell G; Fox SB; Dobrovic A
BMC Cancer; 2008 Feb; 8():59. PubMed ID: 18298804
[TBL] [Abstract][Full Text] [Related]
5. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
6. Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors.
Gotlieb WH; Friedman E; Bar-Sade RB; Kruglikova A; Hirsh-Yechezkel G; Modan B; Inbar M; Davidson B; Kopolovic J; Novikov I; Ben-Baruch G
J Natl Cancer Inst; 1998 Jul; 90(13):995-1000. PubMed ID: 9665148
[TBL] [Abstract][Full Text] [Related]
7. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
[TBL] [Abstract][Full Text] [Related]
8. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer.
Lehrer S; Fodor F; Stock RG; Stone NN; Eng C; Song HK; McGovern M
Br J Cancer; 1998 Sep; 78(6):771-3. PubMed ID: 9743298
[TBL] [Abstract][Full Text] [Related]
9. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
Shiri-Sverdlov R; Oefner P; Green L; Baruch RG; Wagner T; Kruglikova A; Haitchick S; Hofstra RM; Papa MZ; Mulder I; Rizel S; Bar Sade RB; Dagan E; Abdeen Z; Goldman B; Friedman E
Hum Mutat; 2000 Dec; 16(6):491-501. PubMed ID: 11102978
[TBL] [Abstract][Full Text] [Related]
10. A high-throughput protocol for mutation scanning of the BRCA1 and BRCA2 genes.
Hondow HL; Fox SB; Mitchell G; Scott RJ; Beshay V; Wong SQ; ; Dobrovic A
BMC Cancer; 2011 Jun; 11():265. PubMed ID: 21702907
[TBL] [Abstract][Full Text] [Related]
11. Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient.
Tsongalis GJ; Linfert DR; Johnson RC; Ackroyd R; Berman MM; Ricci A
Arch Pathol Lab Med; 1998 Jun; 122(6):548-50. PubMed ID: 9625424
[TBL] [Abstract][Full Text] [Related]
12. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
Oddoux C; Struewing JP; Clayton CM; Neuhausen S; Brody LC; Kaback M; Haas B; Norton L; Borgen P; Jhanwar S; Goldgar D; Ostrer H; Offit K
Nat Genet; 1996 Oct; 14(2):188-90. PubMed ID: 8841192
[TBL] [Abstract][Full Text] [Related]
13. The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of U.S. population data.
Bahar AY; Taylor PJ; Andrews L; Proos A; Burnett L; Tucker K; Friedlander M; Buckley MF
Cancer; 2001 Jul; 92(2):440-5. PubMed ID: 11466700
[TBL] [Abstract][Full Text] [Related]
14. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients.
Fodor FH; Weston A; Bleiweiss IJ; McCurdy LD; Walsh MM; Tartter PI; Brower ST; Eng CM
Am J Hum Genet; 1998 Jul; 63(1):45-51. PubMed ID: 9634504
[TBL] [Abstract][Full Text] [Related]
15. Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations.
Ramus SJ; Fishman A; Pharoah PD; Yarkoni S; Altaras M; Ponder BA
Eur J Surg Oncol; 2001 Apr; 27(3):278-81. PubMed ID: 11373105
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic.
Shih HA; Couch FJ; Nathanson KL; Blackwood MA; Rebbeck TR; Armstrong KA; Calzone K; Stopfer J; Seal S; Stratton MR; Weber BL
J Clin Oncol; 2002 Feb; 20(4):994-9. PubMed ID: 11844822
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
Moslehi R; Chu W; Karlan B; Fishman D; Risch H; Fields A; Smotkin D; Ben-David Y; Rosenblatt J; Russo D; Schwartz P; Tung N; Warner E; Rosen B; Friedman J; Brunet JS; Narod SA
Am J Hum Genet; 2000 Apr; 66(4):1259-72. PubMed ID: 10739756
[TBL] [Abstract][Full Text] [Related]
18. Differences in the characteristics of families with BRCA1 and BRCA2 mutations in Israel.
Rennert G; Dishon S; Rennert HS; Fares F
Eur J Cancer Prev; 2005 Aug; 14(4):357-61. PubMed ID: 16030426
[TBL] [Abstract][Full Text] [Related]
19. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D
Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153
[TBL] [Abstract][Full Text] [Related]
20. No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer.
Wilkens EP; Freije D; Xu J; Nusskern DR; Suzuki H; Isaacs SD; Wiley K; Bujnovsky P; Meyers DA; Walsh PC; Isaacs WB
Prostate; 1999 Jun; 39(4):280-4. PubMed ID: 10344217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
